| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Reduced mortality after allogeneic hematopoietic-cell transplantation.
|
N Engl J Med
|
2010
|
7.20
|
|
2
|
Cytomegalovirus reactivation in critically ill immunocompetent patients.
|
JAMA
|
2008
|
4.19
|
|
3
|
Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation.
|
N Engl J Med
|
2008
|
4.16
|
|
4
|
Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality.
|
Clin Infect Dis
|
2007
|
3.93
|
|
5
|
Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors.
|
Blood
|
2002
|
3.45
|
|
6
|
Combination antifungal therapy for invasive aspergillosis.
|
Clin Infect Dis
|
2004
|
3.23
|
|
7
|
The serum galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with invasive aspergillosis.
|
Clin Infect Dis
|
2013
|
3.15
|
|
8
|
Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy.
|
Clin Infect Dis
|
2004
|
3.01
|
|
9
|
Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients.
|
Ann Intern Med
|
2006
|
2.85
|
|
10
|
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants.
|
Blood
|
2003
|
2.40
|
|
11
|
Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes.
|
Blood
|
2008
|
2.39
|
|
12
|
Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.
|
J Infect Dis
|
2008
|
2.27
|
|
13
|
CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia.
|
Blood
|
2013
|
2.22
|
|
14
|
Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study.
|
Blood
|
2002
|
2.20
|
|
15
|
Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.
|
Lancet Infect Dis
|
2011
|
2.19
|
|
16
|
A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.
|
Lancet Infect Dis
|
2012
|
2.08
|
|
17
|
Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning.
|
Blood
|
2003
|
2.01
|
|
18
|
Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study.
|
Blood
|
2008
|
2.00
|
|
19
|
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.
|
Blood
|
2010
|
1.97
|
|
20
|
High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection.
|
J Infect Dis
|
2002
|
1.93
|
|
21
|
Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors.
|
Transfusion
|
2002
|
1.89
|
|
22
|
Evaluation of published single nucleotide polymorphisms associated with acute GVHD.
|
Blood
|
2012
|
1.88
|
|
23
|
High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy.
|
J Infect Dis
|
2001
|
1.85
|
|
24
|
Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection.
|
Blood
|
2007
|
1.85
|
|
25
|
Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients.
|
Blood
|
2011
|
1.80
|
|
26
|
Quantitative real-time polymerase chain reaction for detection of adenovirus after T cell-replete hematopoietic cell transplantation: viral load as a marker for invasive disease.
|
Clin Infect Dis
|
2007
|
1.66
|
|
27
|
CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.
|
N Engl J Med
|
2013
|
1.66
|
|
28
|
Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study.
|
Biol Blood Marrow Transplant
|
2005
|
1.65
|
|
29
|
Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease.
|
J Infect Dis
|
2013
|
1.60
|
|
30
|
Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis.
|
Transplantation
|
2006
|
1.59
|
|
31
|
Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation.
|
Clin Infect Dis
|
2010
|
1.58
|
|
32
|
Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients.
|
Biol Blood Marrow Transplant
|
2013
|
1.58
|
|
33
|
The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients.
|
Biol Blood Marrow Transplant
|
2009
|
1.56
|
|
34
|
Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation.
|
Clin Infect Dis
|
2005
|
1.52
|
|
35
|
Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients.
|
Clin Infect Dis
|
2007
|
1.51
|
|
36
|
Identification of chromosomally integrated human herpesvirus 6 by droplet digital PCR.
|
Clin Chem
|
2014
|
1.48
|
|
37
|
Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients.
|
Blood
|
2009
|
1.48
|
|
38
|
Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia.
|
Clin Infect Dis
|
2003
|
1.48
|
|
39
|
Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study.
|
Blood
|
2010
|
1.47
|
|
40
|
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.
|
Biol Blood Marrow Transplant
|
2006
|
1.47
|
|
41
|
Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation.
|
Blood
|
2003
|
1.47
|
|
42
|
Coreactivation of Human Herpesvirus 6 and Cytomegalovirus Is Associated With Worse Clinical Outcome in Critically Ill Adults.
|
Crit Care Med
|
2015
|
1.45
|
|
43
|
Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
1.44
|
|
44
|
Cytomegalovirus in hematopoietic stem cell transplant recipients.
|
Infect Dis Clin North Am
|
2010
|
1.44
|
|
45
|
Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis.
|
Med Mycol
|
2012
|
1.44
|
|
46
|
One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation.
|
Blood
|
2007
|
1.43
|
|
47
|
Cytomegalovirus in hematopoietic stem cell transplant recipients.
|
Hematol Oncol Clin North Am
|
2011
|
1.42
|
|
48
|
Quantitation of cytomegalovirus DNA load in dried blood spots correlates well with plasma viral load.
|
J Clin Microbiol
|
2013
|
1.42
|
|
49
|
Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection.
|
Blood
|
2004
|
1.42
|
|
50
|
Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection.
|
Semin Respir Crit Care Med
|
2007
|
1.42
|
|
51
|
Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
1.38
|
|
52
|
Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT.
|
J Infect Dis
|
2010
|
1.36
|
|
53
|
How I treat influenza in patients with hematologic malignancies.
|
Blood
|
2009
|
1.32
|
|
54
|
Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center.
|
Biol Blood Marrow Transplant
|
2004
|
1.31
|
|
55
|
Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation.
|
Blood
|
2003
|
1.31
|
|
56
|
Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses.
|
J Infect Dis
|
2006
|
1.29
|
|
57
|
HHV-6 reactivation and its effect on delirium and cognitive functioning in hematopoietic cell transplantation recipients.
|
Blood
|
2011
|
1.28
|
|
58
|
BK virus infection in hematopoietic stem cell transplant recipients: frequency, risk factors, and association with postengraftment hemorrhagic cystitis.
|
Clin Infect Dis
|
2004
|
1.25
|
|
59
|
Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning.
|
Exp Hematol
|
2003
|
1.25
|
|
60
|
Prolonged outbreak of human parainfluenza virus 3 infection in a stem cell transplant outpatient department: insights from molecular epidemiologic analysis.
|
Biol Blood Marrow Transplant
|
2004
|
1.24
|
|
61
|
BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients.
|
Blood
|
2005
|
1.23
|
|
62
|
Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus.
|
Clin Infect Dis
|
2012
|
1.20
|
|
63
|
Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis.
|
Transplantation
|
2004
|
1.16
|
|
64
|
Parainfluenza virus lower respiratory tract disease after hematopoietic cell transplant: viral detection in the lung predicts outcome.
|
Clin Infect Dis
|
2014
|
1.12
|
|
65
|
Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival.
|
Biol Blood Marrow Transplant
|
2003
|
1.12
|
|
66
|
Polyomavirus nephropathy in native kidneys of non-renal transplant recipients.
|
Am J Transplant
|
2005
|
1.10
|
|
67
|
Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement.
|
Biol Blood Marrow Transplant
|
2013
|
1.09
|
|
68
|
HHV-6 reactivation and associated sequelae after hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
1.08
|
|
69
|
Cyclophosphamide metabolism is affected by azole antifungals.
|
Blood
|
2003
|
1.08
|
|
70
|
An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients.
|
Biol Blood Marrow Transplant
|
2010
|
1.06
|
|
71
|
Respiratory viruses other than influenza virus: impact and therapeutic advances.
|
Clin Microbiol Rev
|
2008
|
1.05
|
|
72
|
Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes.
|
Clin Infect Dis
|
2013
|
1.05
|
|
73
|
CMV in critically ill patients: pathogen or bystander?
|
Rev Med Virol
|
2010
|
1.04
|
|
74
|
Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs.
|
Haematologica
|
2011
|
1.03
|
|
75
|
Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation.
|
Haematologica
|
2009
|
1.03
|
|
76
|
Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products.
|
Blood
|
2003
|
1.02
|
|
77
|
Respiratory failure caused by 2009 novel influenza A/H1N1 in a hematopoietic stem-cell transplant recipient: Detection of extrapulmonary H1N1 RNA and use of intravenous peramivir.
|
Ann Intern Med
|
2010
|
1.01
|
|
78
|
Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation.
|
Cytotherapy
|
2012
|
1.01
|
|
79
|
Association between immune recovery uveitis and a diverse intraocular cytomegalovirus-specific cytotoxic T cell response.
|
J Infect Dis
|
2002
|
0.99
|
|
80
|
Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation.
|
Br J Haematol
|
2003
|
0.99
|
|
81
|
Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning.
|
Biol Blood Marrow Transplant
|
2006
|
0.97
|
|
82
|
Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease.
|
J Infect Dis
|
2007
|
0.97
|
|
83
|
Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.
|
Ann Intern Med
|
2015
|
0.96
|
|
84
|
Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study.
|
Clin Infect Dis
|
2007
|
0.96
|
|
85
|
Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
0.95
|
|
86
|
Compartmentalized cytomegalovirus replication and transmission in the setting of maternal HIV-1 infection.
|
Clin Infect Dis
|
2013
|
0.93
|
|
87
|
Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus.
|
Biol Blood Marrow Transplant
|
2010
|
0.93
|
|
88
|
Impact of HLA A2 and cytomegalovirus serostatus on outcomes in patients with leukemia following matched-sibling myeloablative allogeneic hematopoietic cell transplantation.
|
Haematologica
|
2006
|
0.91
|
|
89
|
Impact of human cytomegalovirus (CMV) infection on immune response to pandemic 2009 H1N1 influenza vaccine in healthy adults.
|
J Med Virol
|
2013
|
0.89
|
|
90
|
Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed?
|
Curr Opin Virol
|
2011
|
0.89
|
|
91
|
Persistent fever in patients with neutropenia.
|
N Engl J Med
|
2002
|
0.88
|
|
92
|
Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes.
|
Biol Blood Marrow Transplant
|
2008
|
0.88
|
|
93
|
Factors affecting antibody levels after allogeneic hematopoietic cell transplantation.
|
Blood
|
2002
|
0.87
|
|
94
|
Self-collection of foam nasal swabs for respiratory virus detection by PCR among immunocompetent subjects and hematopoietic cell transplant recipients.
|
J Clin Microbiol
|
2012
|
0.86
|
|
95
|
Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2002
|
0.86
|
|
96
|
Influenza viral RNA detection in blood as a marker to predict disease severity in hematopoietic cell transplant recipients.
|
J Infect Dis
|
2012
|
0.85
|
|
97
|
Development of multiplexed real-time quantitative polymerase chain reaction assay for detecting human adenoviruses.
|
Diagn Microbiol Infect Dis
|
2008
|
0.84
|
|
98
|
Pretransplantation respiratory syncytial virus infection: impact of a strategy to delay transplantation.
|
Clin Infect Dis
|
2004
|
0.84
|
|
99
|
Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation.
|
Biol Blood Marrow Transplant
|
2005
|
0.84
|
|
100
|
Congenital cytomegalovirus infection in pediatric hearing loss.
|
Arch Otolaryngol Head Neck Surg
|
2011
|
0.83
|
|
101
|
Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007.
|
Herpes
|
2008
|
0.83
|
|
102
|
WU and KI polyomaviruses in respiratory samples from allogeneic hematopoietic cell transplant recipients.
|
Emerg Infect Dis
|
2012
|
0.83
|
|
103
|
Polymorphisms in the genes encoding chemokine receptor 5, interleukin-10, and monocyte chemoattractant protein 1 contribute to cytomegalovirus reactivation and disease after allogeneic stem cell transplantation.
|
J Clin Microbiol
|
2006
|
0.82
|
|
104
|
Species-specific recognition of Aspergillus fumigatus by Toll-like receptor 1 and Toll-like receptor 6.
|
J Infect Dis
|
2012
|
0.82
|
|
105
|
Improving hematopoietic cell transplant outcomes in a new era of genomic research.
|
Biol Blood Marrow Transplant
|
2009
|
0.81
|
|
106
|
Cytomegalovirus infections in cancer patients receiving granulocyte transfusions.
|
Blood
|
2002
|
0.80
|
|
107
|
Transferred herpes simplex virus immunity after stem-cell transplantation: clinical implications.
|
J Infect Dis
|
2003
|
0.79
|
|
108
|
Donor serostatus and CMV infection and disease among recipients of prophylactic granulocyte transfusions.
|
Blood
|
2003
|
0.79
|
|
109
|
Immunologic predictors of late cytomegalovirus disease after solid organ transplantation--an elusive goal?
|
J Infect Dis
|
2007
|
0.79
|
|
110
|
Postexposure prophylaxis against varicella-zoster virus infection among recipients of hematopoietic stem cell transplant: unresolved issues.
|
Infect Control Hosp Epidemiol
|
2004
|
0.78
|
|
111
|
Reanalysis of TransVax immunogenicity.
|
Lancet Infect Dis
|
2013
|
0.78
|
|
112
|
Detection of adeno-associated virus viremia in hematopoietic cell transplant recipients.
|
J Infect Dis
|
2011
|
0.77
|
|
113
|
Evaluation of therapeutics for RSV: an important step forward.
|
Am J Respir Crit Care Med
|
2010
|
0.76
|
|
114
|
Postexposure prophylaxis against varicella zoster virus infection among hematopoietic stem cell transplant recipients.
|
Biol Blood Marrow Transplant
|
2006
|
0.76
|
|
115
|
Long-term care after hematopoietic-cell transplantation in adults.
|
N Engl J Med
|
2002
|
0.75
|
|
116
|
An outbreak of varicella with likely breakthrough disease in a population of pediatric cancer patients.
|
Infect Control Hosp Epidemiol
|
2008
|
0.75
|
|
117
|
Reply to Mikulska et al.
|
Clin Infect Dis
|
2013
|
0.75
|
|
118
|
Reply to King and Stover.
|
Clin Infect Dis
|
2013
|
0.75
|